170 related articles for article (PubMed ID: 10304999)
1. Developing drug information for patients.
Hecht A
FDA Consum; 1977 Sep; 11(7):16-9. PubMed ID: 10304999
[No Abstract] [Full Text] [Related]
2. Will PPIs affect your patients' attitudes?
Patient Care; 1979 Feb; 13(3):190-1, 195-6. PubMed ID: 10240261
[No Abstract] [Full Text] [Related]
3. Rx with a dose of info.
Miller RW
FDA Consum; 1980 Nov; 14(9):22-3. PubMed ID: 10309292
[TBL] [Abstract][Full Text] [Related]
4. Prescription drug products; patient labeling requirements: proposed rule.
Fed Regist; 1979 Jul; 44(131 Pt 2):40015-41. PubMed ID: 10242793
[No Abstract] [Full Text] [Related]
5. Patient package inserts: the proper prescription?
Rowe HM
Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
[No Abstract] [Full Text] [Related]
6. Informing patients about drugs: a wrong way and a right way.
Woodson DW
Med World News; 1979 Jun; 20(13):6. PubMed ID: 10242286
[No Abstract] [Full Text] [Related]
7. Did FDA jump the gun?
Archambault GF
Hosp Formul; 1977 Oct; 12(10):722. PubMed ID: 10305387
[No Abstract] [Full Text] [Related]
8. The status of unit-of-use in Europe and the United States: an evolution in drug dispensing.
Archambault GF
Hosp Formul; 1979 Jan; 14(1):70-1, 75-6, 78-9. PubMed ID: 10297341
[No Abstract] [Full Text] [Related]
9. FDA's Rx for better medication information.
Farley D
FDA Consum; 1995 Nov; 29(9):5-10. PubMed ID: 10152787
[TBL] [Abstract][Full Text] [Related]
10. FDA chief says demand by patients for more drug information is genuine.
Health Educ Rep; 1980 Jul; 2(15):4-5. PubMed ID: 10247629
[No Abstract] [Full Text] [Related]
11. FDA puts forth proposal to mandate patient information.
Wechsler J
Formulary; 1995 Oct; 30(10):622-3. PubMed ID: 10151725
[No Abstract] [Full Text] [Related]
12. A means to provide patient education: "Rx package inserts, patient package inserts, device labeling".
Sherman M
ONA J; 1979 Aug; 6(8):326-9. PubMed ID: 257297
[No Abstract] [Full Text] [Related]
13. Educating patients about their medications: the potential and limitations of written drug information.
Shrank WH; Avorn J
Health Aff (Millwood); 2007; 26(3):731-40. PubMed ID: 17485751
[TBL] [Abstract][Full Text] [Related]
14. Cisapride and patient information leaflets.
Sukkari SR; Sasich LD
CMAJ; 2001 May; 164(9):1276-8; author reply 1278-9. PubMed ID: 11341134
[No Abstract] [Full Text] [Related]
15. Progestational drug products for human use; requirements for labeling directed to the patient. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 Nov; 64(220):62110-2. PubMed ID: 11010691
[TBL] [Abstract][Full Text] [Related]
16. FDA acts on estrogen, progestin labeling.
FDA Consum; 1977 Nov; 11(9):3. PubMed ID: 10305006
[No Abstract] [Full Text] [Related]
17. Improving prescription drug labeling.
Wolf MS; Bailey SC
N C Med J; 2007; 68(5):340-2. PubMed ID: 18183755
[No Abstract] [Full Text] [Related]
18. Literacy demands of product information intended to supplement television direct-to-consumer prescription drug advertisements.
Kaphingst KA; Rudd RE; DeJong W; Daltroy LH
Patient Educ Couns; 2004 Nov; 55(2):293-300. PubMed ID: 15530767
[TBL] [Abstract][Full Text] [Related]
19. Off-label pharmaceutical use: balancing information, risks, and benefits.
Kozma CM
Manag Care Interface; 2004 Jan; 17(1):29-30. PubMed ID: 15035597
[No Abstract] [Full Text] [Related]
20. The legal status of patient package inserts.
Whitman JA
Hosp Formul; 1978 Oct; 13(10):789-91. PubMed ID: 10238809
[No Abstract] [Full Text] [Related]
[Next] [New Search]
